-
Mashup Score: 0
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Mary Jo Lechowicz, Winship Cancer institute o…
Source: YouTubeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Mary Jo Lechowicz, Winship Cancer institute of Emory University, Atlanta, US. We asked, How can we address treatment disparities in patients with T-cell lymphoma?
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
👀 During #SOHO2021, the #LymphomaHub was pleased to speak to @MaryjoLechowicz, @WinshipAtEmory. We asked, How can we address treatment disparities in patients with T-cell #lymphoma? 👉 https://t.co/50mBI0uXDu 👈 #lymsm #lymphoma
-
-
Mashup Score: 0How do you use MRD to guide treatment decisions? - 3 year(s) ago
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Othman Al-Sawaf, University Hospital Cologne, Cologne, DE. We asked, How do you use minimal residual disease (MRD) to guide treatment decisions?
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📹 #SOHO2021 | The @lymphomahub was pleased to speak to @Othman_Al_Sawaf, @UniCologne. We asked, How do you use minimal residual disease (MRD) to guide treatment decisions? 👇 #lymsm #CLL https://t.co/qtFcPeRMxx
-
-
Mashup Score: 1
Ola Landgren, MD, PhD, of Sylvester Comprehensive Cancer Center, University of Miami, FL, summarises the results of the Agricultural Health…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#MGUS rate significantly ⬆️ in young farmers compared to demographically similar men @DrOlaLandgren (@SylvesterCancer) shares results of the Agricultural Health Study assessing pesticide exposure & MGUS incidence: https://t.co/8TCRmz7YNt @SocietyofHemOnc #SOHO2021 #HemOnc #MMsm
-
-
Mashup Score: 1Therapeutic Challenge Exists With Treating Accelerated Phase Myeloproliferative Neoplasms - 3 year(s) ago
There remains a therapeutic challenge with understanding and treating patients with accelerated myeloproliferative neoplasms.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
There remains a therapeutic challenge with understanding and treating patients with accelerated myeloproliferative neoplasms. @SocietyofHemOnc #soho2021 https://t.co/VvrSswzuB4
-
-
Mashup Score: 0What are the future prospects for FLT3 mutated AML? - 3 year(s) ago
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Alexander Perl, University of Pennsylvania, Philadelphia, US. We Asked, What are the future prospects for FLT3 mutated acute myeloid leukemia (AML)?
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🧬 During #SOHO2021, the @AML_Hub spoke to Alexander Perl, @Penn. We Asked, What are the future prospects for FLT3 mutated #AML? 👉 https://t.co/eUKK2rUDzG 👈 #leusm #AMLsm #leukemia https://t.co/rlvB31USWc
-
-
Mashup Score: 1Evaluating therapies in MDS - 3 year(s) ago
Andrew Brunner, MD, of Massachusetts General Hospital, Boston, MA, discusses the use and pitfalls of hypomethylating agents (HMAs) including azacitidine…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
💊Evaluating therapies in #MDS💊 @andrewbrunner (@MGHCancerCenter) describes the criteria used to assess therapies for the treatment of #MDS: https://t.co/f0GzHPX2Go @SocietyofHemOnc #SOHO2021 #HemOnc #MDSsm
-
-
Mashup Score: 15
Nicole Lamanna, MD, Columbia University Medical Center, New York, NY, discusses clinical evidence relating to the treatment of chronic lymphocytic…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Comparing BTK & BCL-2 inhibitor outcomes in different CLL subgroups Nicole Lamanna (@ColumbiaMed) discusses clinical evidence relating to the treatment of #CLL in older, TN, & younger patients: https://t.co/n9hO8D9ezo @SocietyofHemOnc #SOHO2021 #HemOnc #CLLsm #Leukemia #LeuSM
-
-
Mashup Score: 1
Jessica Okosun, MA, MB BChir, MRCP, FRCPath, PhD, of the Barts Cancer Institute, London, UK, gives an overview of the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
💥The relevance of #FollicularLymphoma pathogenesis in clinical practice💥 w @Jessica_Okosun (@BartsHospital @QMBCI): 👉https://t.co/YlQiarM9ts @SocietyofHemOnc #SOHO2021 #HemOnc #LYMsm #Lymphoma
-
-
Mashup Score: 0Latest updates from the Phase I/II BRUIN study - 3 year(s) ago
Catherine C. Coombs, MD, The University of North Carolina Cancer Center, Chapel Hill, NC, shares the latest data from the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Phase I/II BRUIN study of pirtobrutinib in previously treated #CLL #SLL & #NHL ORR 63% & >80% RR when receiving pirtobrutinib for >10 months @calliecoombsmd (@UNC_Lineberger) shares the latest updates: https://t.co/O08wUaKec2 #SOHO2021 #HemOnc #CLLsm #Leukemia #Leusm #Lymphoma
-
👀 Have you watched this? During #SOHO2021, the #LymphomaHub spoke with @MaryjoLechowicz, @WinshipAtEmory. We asked, How can we address treatment disparities in patients with T-cell #lymphoma? 👉https://t.co/uPqklQMm1R 👈 #lymsm